WO2011154830A3 - Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa - Google Patents

Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa Download PDF

Info

Publication number
WO2011154830A3
WO2011154830A3 PCT/IB2011/001415 IB2011001415W WO2011154830A3 WO 2011154830 A3 WO2011154830 A3 WO 2011154830A3 IB 2011001415 W IB2011001415 W IB 2011001415W WO 2011154830 A3 WO2011154830 A3 WO 2011154830A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphodiesterase inhibitors
transmucosal administration
pharmaceutical form
relates
methylpiperazine
Prior art date
Application number
PCT/IB2011/001415
Other languages
English (en)
French (fr)
Other versions
WO2011154830A2 (es
Inventor
Jorge Hernando Useche Ovalle
Rafael ZUÑIGA MARTINEZ
Cristina Salazar Zarta
Original Assignee
Betazone Laboratories Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betazone Laboratories Llc. filed Critical Betazone Laboratories Llc.
Priority to MX2012014237A priority Critical patent/MX2012014237A/es
Publication of WO2011154830A2 publication Critical patent/WO2011154830A2/es
Publication of WO2011154830A3 publication Critical patent/WO2011154830A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una nueva forma farmacéutica de INHIBIDORES DE LA FOSFODIESTERASA para administración transmucosa. Más particularmente, la presente invención se refiere a una composición farmacéutica líquida de tipo liposomal de INHIBIDORES DE LA FOSFODIESTERASA que contiene citrato de 1 - ((3 - (6,7 - dihidro - 1 - metil - 7 - oxo - 3 - propil - 1 H-pirazolo (4,3 - d) pirimidin - 5 - il) - 4 - etoxifenil) sulfonil) - 4- metilpiperazina, como agente activo asociado con uno o más excipientes farmacéuticamente aceptables.
PCT/IB2011/001415 2010-06-08 2011-06-03 Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa WO2011154830A2 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2012014237A MX2012014237A (es) 2010-06-08 2011-06-03 Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CO10068719 2010-06-08
CO10068719A CO6280050A1 (es) 2010-06-08 2010-06-08 Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa

Publications (2)

Publication Number Publication Date
WO2011154830A2 WO2011154830A2 (es) 2011-12-15
WO2011154830A3 true WO2011154830A3 (es) 2012-03-01

Family

ID=44084021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/001415 WO2011154830A2 (es) 2010-06-08 2011-06-03 Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa

Country Status (3)

Country Link
CO (1) CO6280050A1 (es)
MX (1) MX2012014237A (es)
WO (1) WO2011154830A2 (es)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000051572A1 (en) * 1999-03-03 2000-09-08 Elan Pharma International Ltd. Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US20020004498A1 (en) * 1997-10-28 2002-01-10 Doherty Paul C. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO2002049617A2 (en) * 2000-12-20 2002-06-27 Biozone Laboratories, Inc. Self forming, thermodynamically stable liposomes and their applications
CN101269212A (zh) * 2008-04-30 2008-09-24 上海麟翔生物技术有限公司 一种可吞咽的漱口液
US20090324698A1 (en) * 2004-10-18 2009-12-31 Polymun Scientific Immunbiologische Forschung Gmbh Liposomal composition comprising an active ingredient for relaxing smooth muscle, the production of this composition and the therapeutic use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020004498A1 (en) * 1997-10-28 2002-01-10 Doherty Paul C. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO2000051572A1 (en) * 1999-03-03 2000-09-08 Elan Pharma International Ltd. Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
WO2002049617A2 (en) * 2000-12-20 2002-06-27 Biozone Laboratories, Inc. Self forming, thermodynamically stable liposomes and their applications
US20090324698A1 (en) * 2004-10-18 2009-12-31 Polymun Scientific Immunbiologische Forschung Gmbh Liposomal composition comprising an active ingredient for relaxing smooth muscle, the production of this composition and the therapeutic use thereof
CN101269212A (zh) * 2008-04-30 2008-09-24 上海麟翔生物技术有限公司 一种可吞咽的漱口液

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Database accession no. 2008-M66480[75] *

Also Published As

Publication number Publication date
WO2011154830A2 (es) 2011-12-15
CO6280050A1 (es) 2011-05-20
MX2012014237A (es) 2013-01-18

Similar Documents

Publication Publication Date Title
MX2015010971A (es) Derivado novedoso de pirazol.
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
WO2009024611A3 (en) 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
WO2009084021A3 (en) Ophthalmic composition comprising a prostaglandin
TN2013000257A1 (en) Immunosuppressant formulations
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2010049449A3 (en) Novel salts of sunitinib
MX2015005762A (es) Producto de comicronizacion que comprende acetato de ulipristal.
WO2009060952A1 (ja) 新規製剤
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
TW200800977A (en) A new salt
MX2021000769A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
WO2013188465A3 (en) Treating drug addiction and preventing drug relapse
WO2005097192A3 (en) Active substance combination of a carbinol compound and an opioid
WO2011154830A3 (es) Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa
WO2010029093A3 (en) Compositions for percutaneous administration

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/014237

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11792018

Country of ref document: EP

Kind code of ref document: A2